MA31062B1 - Agents tensioactifs reconstitues presentant des proprietes ameliorees. - Google Patents

Agents tensioactifs reconstitues presentant des proprietes ameliorees.

Info

Publication number
MA31062B1
MA31062B1 MA31854A MA31854A MA31062B1 MA 31062 B1 MA31062 B1 MA 31062B1 MA 31854 A MA31854 A MA 31854A MA 31854 A MA31854 A MA 31854A MA 31062 B1 MA31062 B1 MA 31062B1
Authority
MA
Morocco
Prior art keywords
improved properties
reconstituted surfactants
reconstituted
relates
surfactants
Prior art date
Application number
MA31854A
Other languages
Arabic (ar)
English (en)
Inventor
Jan Johansson
Tore Curstedt
Bengt Robertson
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39079026&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31062(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of MA31062B1 publication Critical patent/MA31062B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/395—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Fire-Extinguishing Compositions (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)

Abstract

La présente invention porte sur un agent tensioactif reconstitué comportant un support lipidique, un analogue polypeptidique de la protéine d'agent tensioactif native sp-c, et un analogue polypeptidique de la protéine d'agent tensioactif native sp-b. L'invention porte également sur les compositions pharmaceutiques dudit agent et sur leur utilisation pour le traitement ou la prophylaxie de rds et d'autres maladies respiratoires.
MA31854A 2006-10-13 2009-05-08 Agents tensioactifs reconstitues presentant des proprietes ameliorees. MA31062B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06021521 2006-10-13
PCT/IB2007/002841 WO2008044109A1 (fr) 2006-10-13 2007-09-28 Agents tensioactifs reconstitués présentant des propriétés améliorées

Publications (1)

Publication Number Publication Date
MA31062B1 true MA31062B1 (fr) 2010-01-04

Family

ID=39079026

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31854A MA31062B1 (fr) 2006-10-13 2009-05-08 Agents tensioactifs reconstitues presentant des proprietes ameliorees.

Country Status (35)

Country Link
US (2) US8183210B2 (fr)
EP (1) EP2078038B1 (fr)
JP (2) JP5405307B2 (fr)
KR (1) KR101328851B1 (fr)
CN (2) CN103169947B (fr)
AR (2) AR063263A1 (fr)
AU (1) AU2007306075B2 (fr)
BR (1) BRPI0715317B1 (fr)
CA (1) CA2666344C (fr)
CL (1) CL2007002931A1 (fr)
CO (1) CO6400235A2 (fr)
CY (1) CY1114716T1 (fr)
DK (1) DK2078038T3 (fr)
EA (1) EA015802B1 (fr)
ES (1) ES2438727T3 (fr)
GE (1) GEP20125531B (fr)
HR (1) HRP20140052T1 (fr)
IL (1) IL198075A (fr)
JO (1) JO2963B1 (fr)
MA (1) MA31062B1 (fr)
ME (2) MEP12109A (fr)
MX (1) MX343064B (fr)
MY (1) MY148127A (fr)
NO (1) NO342038B1 (fr)
NZ (1) NZ576189A (fr)
PE (1) PE20081184A1 (fr)
PL (1) PL2078038T3 (fr)
PT (1) PT2078038E (fr)
RS (1) RS53172B (fr)
SI (1) SI2078038T1 (fr)
TN (1) TN2009000099A1 (fr)
TW (1) TWI388333B (fr)
UA (1) UA94477C2 (fr)
WO (1) WO2008044109A1 (fr)
ZA (1) ZA200902481B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008011559A2 (fr) 2006-07-20 2008-01-24 University Of Rochester Tensioactif pulmonaire synthetique et utilisation associée
EP1997502A1 (fr) * 2007-06-01 2008-12-03 CHIESI FARMACEUTICI S.p.A. Agents tensioactifs reconstitués dotés de propriétés améliorées
US8399406B2 (en) * 2009-06-05 2013-03-19 Chiesi Farmaceutici S.P.A. Reconstituted surfactant composition containing analogs of surfactant protein B (SP-B) and surfactant protein C (SP-C)
CN101948526B (zh) * 2010-09-02 2012-12-05 华东理工大学 一种肺泡表面活性蛋白质(sp-b和sp-c)的分离纯化方法
WO2013120058A2 (fr) * 2012-02-09 2013-08-15 University Of Rochester Nouveaux peptides sp-b et sp-c, tensioactifs pulmonaires synthétiques, et leurs utilisations
US20130303726A1 (en) 2012-04-17 2013-11-14 Chiesi Farmaceutici S.P.A. Method for the preparation of surfactant peptides
US9074018B2 (en) 2012-11-21 2015-07-07 Chiesi Farmaceutici S.P.A. Reconstituted pulmonary surfactants
EP3393489B1 (fr) 2015-12-17 2021-09-01 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Surfactant pulmonaire synthétique à stabilité et efficacité augmentées
CA3016810C (fr) 2016-03-07 2024-04-02 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Compositions et procedes pour l'administration d'agonistes de pparv, peptides tensioactifs et phopholipides
BR112019003673A2 (pt) 2016-08-24 2019-05-21 Chiesi Farmaceutici S.P.A. formulação farmacêutica, uso de uma formulação farmacêutica e método para evitar o aumento da viscosidade durante o armazenamento de uma formulação farmacêutica
US12606609B2 (en) 2020-01-28 2026-04-21 Chiesi Farmaceutici S.P.A. Polypeptides having improved properties
WO2022082082A2 (fr) * 2020-10-16 2022-04-21 Sherwood Russ Lehrman Compositions de traitement pulmonaire
WO2025024609A1 (fr) * 2023-07-25 2025-01-30 Biosuperior Technology, Inc. Polypeptides pour compositions de tensioactifs pulmonaires

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08512056A (ja) * 1993-06-30 1996-12-17 ジェネンテク・インコーポレイテッド リポソームの製造法
IT1308180B1 (it) * 1999-02-12 2001-12-07 Chiesi Farma Spa Peptidi sintetici aventi la capacita' di diminuire la tensionesuperficiale e loro impiego nella preparazione di un surfattante
US7065342B1 (en) * 1999-11-23 2006-06-20 Gofigure, L.L.C. System and mobile cellular telephone device for playing recorded music
ITMI20021058A1 (it) * 2002-05-17 2003-11-17 Chiesi Farma Spa Miscele di lipidi sintetici ottimizzate per la preparazione di un surfattante ricostituito
EP1481665A1 (fr) * 2003-05-30 2004-12-01 CHIESI FARMACEUTICI S.p.A. Nouveaux mélanges lipidiques pour tensioactifs synthétiques
WO2008011559A2 (fr) * 2006-07-20 2008-01-24 University Of Rochester Tensioactif pulmonaire synthetique et utilisation associée
EP1997502A1 (fr) * 2007-06-01 2008-12-03 CHIESI FARMACEUTICI S.p.A. Agents tensioactifs reconstitués dotés de propriétés améliorées
EP2022798A1 (fr) 2007-08-09 2009-02-11 CHIESI FARMACEUTICI S.p.A. Peptides synthétiques de surfactant pulmonaire

Also Published As

Publication number Publication date
JP5405307B2 (ja) 2014-02-05
ES2438727T3 (es) 2014-01-20
US8183210B2 (en) 2012-05-22
WO2008044109A1 (fr) 2008-04-17
CN103169947B (zh) 2014-10-29
CO6400235A2 (es) 2012-03-15
MY148127A (en) 2013-02-28
JP2010505937A (ja) 2010-02-25
JO2963B1 (en) 2016-03-15
UA94477C2 (ru) 2011-05-10
RS53172B (sr) 2014-06-30
CN103169947A (zh) 2013-06-26
BRPI0715317A2 (pt) 2013-07-09
MX2009003638A (es) 2009-04-22
EP2078038A1 (fr) 2009-07-15
US20130079275A1 (en) 2013-03-28
KR101328851B1 (ko) 2013-11-14
CY1114716T1 (el) 2016-10-05
HK1185274A1 (en) 2014-02-14
CL2007002931A1 (es) 2008-03-24
IL198075A0 (en) 2011-08-01
AU2007306075A1 (en) 2008-04-17
HK1134497A1 (en) 2010-04-30
NO342038B1 (no) 2018-03-19
TW200824705A (en) 2008-06-16
KR20090083892A (ko) 2009-08-04
NZ576189A (en) 2011-09-30
GEP20125531B (en) 2012-05-25
IL198075A (en) 2016-04-21
DK2078038T3 (da) 2013-12-02
MX343064B (es) 2016-10-24
ME02326B (me) 2016-06-20
CA2666344C (fr) 2017-04-18
SI2078038T1 (sl) 2014-02-28
US20100004173A1 (en) 2010-01-07
TN2009000099A1 (en) 2010-08-19
PL2078038T3 (pl) 2014-05-30
CA2666344A1 (fr) 2008-04-17
TWI388333B (zh) 2013-03-11
BRPI0715317B1 (pt) 2021-10-05
PT2078038E (pt) 2013-12-12
MEP12109A (en) 2011-12-20
HRP20140052T1 (hr) 2014-02-28
EA200900373A1 (ru) 2009-10-30
AR063263A1 (es) 2009-01-14
CN101522711A (zh) 2009-09-02
US9238058B2 (en) 2016-01-19
JP2013241449A (ja) 2013-12-05
CN101522711B (zh) 2013-11-13
NO20091441L (no) 2009-06-23
AR113422A2 (es) 2020-04-29
EA015802B1 (ru) 2011-12-30
EP2078038B1 (fr) 2013-11-20
PE20081184A1 (es) 2008-09-26
ZA200902481B (en) 2010-07-28
AU2007306075B2 (en) 2012-08-09

Similar Documents

Publication Publication Date Title
ES2846789T3 (es) Composiciones que contienen complejos HC-HA/PTX3 y métodos de uso de los mismos
TN2009000099A1 (en) Reconstituted surfactants having improved properties
MX2009012675A (es) Tensioactivos reconstituidos que tienen propiedades mejoradas.
MA33374B1 (fr) Composition de surfactant reconstitué améliorée contenant des analogues de la protéine b du surfactant (sp-b) et de la protéine c du surfactant (sp-c)
ATE242633T1 (de) Dialkylfumarate zur behandlung von autoimmunerkrankungen
WO1998033509A3 (fr) Proprietes utiles de la lactoferrine humaine et de variants de celle-ci
DE60042215D1 (de) Zusammensetzungen und verfahren zur behandlung der parkinson-krankheit
MA30041B1 (fr) Immunoglobulines
US6818621B2 (en) Osteopontin-derived chemotactic and inhibitory agents and uses therefor
WO2014168253A1 (fr) Inhibiteur de la formation de pièges extracellulaires dans les leucocytes
ATE313562T1 (de) Antimicrobielle wirkung des ersten kationischen cluster des menschlichen lactoferrins
TW201004639A (en) Treatment of rheumatoid arthritis with mammal beta defensins
MA29625B1 (fr) Immunoglobulines
AU2017252344A1 (en) Diagnosis of immune_activation using CLEVER-1, TNF-alpha and HLA-DR binding agents
US20240041987A1 (en) Novel bioactive peptide combinations and uses thereof
JP2013530990A (ja) 創傷治療に係るラクトフェリンの配列、組成物、及び方法
CA3155100A1 (fr) Peptides de fusion d'il-15 utilises pour traiter le cancer
CA3201966A1 (fr) Pretraitement de csm avec un agoniste de ppar?/? pour le traitement des lesions d'ischemie-reperfusion
PT1317273E (pt) Utilizacao de quimera il-6r/il-6 na doenca de huntington
KR101169850B1 (ko) 트로락스를 포함하는 골 대사성 질환 또는 골 전이성 암 질환 예방 및 치료용 약제학적 조성물
JP7863335B2 (ja) 細胞外マトリックスに結合するＩＬ－１受容体アンタゴニスト（ＩＬ－１Ｒａ）融合タンパク質
WO2002098454A3 (fr) Molecules recombinees a immunogenicite reduite, procedes et produits intermediaires pour les obtenir et leur utilisation dans des compositions pharmaceutiques et des outils diagnostiques
Samy et al. Wound Healing Activity and Mechanisms of Action of an Antibacterial
IL175019A0 (en) Cxcl8 antagonists, their preparation and use
BRPI0516935A (pt) secretagogos de gh e usos dos mesmos